爱玛客 ARMK 深 沪
等待开盘 02-10 09:30:00 美东时间
38.80
+0.070
+0.18%
华盛通- 最 高38.88
- 今 开38.61
- 成交量 889.20万股
- 最 低 38.25
- 昨 收 38.73
- 总市值 101.97亿
- 52周最高 44.265
- 市盈率 静 31.78
- 换手率 0.00%
- 52周最低 29.59
- 委 比 39.58%
- 总股本 2.63亿
- 历史最高 44.265
- 量 比 1.72
- 振 幅 1.63%
- 历史最低 -2.46
- 每 手 1
- 风险率 2.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多A Glimpse of Aramark's Earnings Potential
Aramark (NYSE:ARMK) will release its quarterly earnings report on Tuesday, 2026...
今天 00:02
UPDATE 2-Catering group Compass' shares fall as AI concerns overshadow revenue beat
UPDATE 2-Catering group Compass' shares fall as AI concerns overshadow revenue beat Updates throughout with details on AI disruption, shares and analyst comment Shares hit three-year low despite revenue beat Concerns over AI disruption hurt investor sentiment Compass reaffirms fiscal 2026 guidance B
02-05 15:21
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
Morgan Stanley Maintains Equal-Weight on Aramark, Raises Price Target to $44
Morgan Stanley analyst Toni Kaplan maintains Aramark (NYSE:ARMK) with a Equal-Weight and raises the price target from $43 to $44.
2025-12-17 21:47
InvestorsTape.com- VENU and Live Nation Take the Big Stage
Venu Holding Corporation (VENU) has signed a transformative Operator Agreement with Live Nation, marking a significant step in its national expansion. Under the deal, Live Nation becomes the exclusive operator and booking agent for VENU's 20,000-capacity Sunset Amphitheater in McKinney, Texas. This partnership enhances VENU's growth trajectory, profitability, and financial visibility, leveraging Live Nation's global booking power and artist relat...
2025-12-12 15:13
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
2025-11-20 10:28
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
2025-11-19 11:01
Baird Maintains Outperform on Aramark, Lowers Price Target to $46
Baird analyst Andrew Wittmann maintains Aramark (NYSE:ARMK) with a Outperform and lowers the price target from $47 to $46.
2025-11-19 00:01
